Palisade Bio Inc. Common Stock (PALI)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power and a margin of safety. Palisade Bio is a clinical-stage biotech with 14 employees and a lead candidate, PALI-2108, in Phase 1b for inflammatory bowel disease. It has no approved product and no durable revenue. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $500,000 and net income was -$10.6M. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was -$9.6M. For FY2025 ended 2025-12-31, net loss was -$16.8M; FY2024, -$14.4M; FY2023, -$12.3M on $250,000 of revenue. The Lynch category is none because it lost money in each of the last four years. Trailing free cash flow is -$18.2M, a -7.1% FCF yield. ROE is -51.37%, ROCE is -32.98%, and the FairStock Score is 26/100. The Piotroski F-Score is only 2/9. Debt is zero, and the Altman Z-Score is 26.56, but for a pre-revenue biotech that gives little comfort; the real risk is clinical and financing risk. At $1.47 on 2026-10-13, market cap is $256.2M. FairStock's Graham Number is $3.20, showing 54.06% margin of safety, but I cannot anchor on that when the P/E of 2.26 and EPS of $0.65 conflict with filed losses. The competitive moat is potential, not proven. I would watch cash burn, trial data, and dilution.

In plain English: Palisade Bio is a small drug company testing an oral medicine for inflammatory bowel diseases. It has almost no revenue and has lost money for years, so the business looks weak and unproven. At $1.47, the price looks speculative; one simple value check says it may be cheap, but that check matters little for a company with no profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer